Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus FLOVENT HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus FLOVENT HFA.
FLOVENT DISKUS 250 vs FLOVENT HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Fluticasone propionate is a synthetic corticosteroid that binds to glucocorticoid receptors, increasing the synthesis of lipocortins, which inhibit phospholipase A2, thereby reducing arachidonic acid release and decreasing prostaglandin and leukotriene production. It also suppresses inflammatory cell migration and cytokine release, leading to reduced airway inflammation and hyperreactivity.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
Adult: 88-880 mcg twice daily via oral inhalation; typical starting dose: 88 mcg twice daily for patients previously on bronchodilators alone, 220 mcg twice daily for patients on inhaled corticosteroids.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Terminal elimination half-life is approximately 7.8 hours (range 6.5-10.6 hours) after inhalation, supporting twice-daily dosing.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Primarily fecal (approximately 60-80%) after biliary elimination, with renal excretion accounting for <5% as unchanged drug and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid